Berkshire Biomedical Corporation

Berkshire Biomedical Corporation is developing drug dispensing technologies designed to accurately and precisely deliver oral liquid drugs. This is accomplished by pioneering the use of biometric technologies, combined with cloud-based and physician-enabled remote management systems, to provide accurate personalized medication delivery to only the authenticated Intended User. The Company’s lead product under development, the Computerized Oral Prescription Administration System (COPA™), is an automated oral liquid dispensing system designed to deliver controlled and non-controlled oral liquid medications to only the authenticated Intended User upon confirmation of dual biometric identifications (fingerprint and dentition).

Three overarching features combine to make the COPA system unique: security, compliance support (metrics) with remote monitoring and precise oral liquid dispensing. The Company intends to initially seek opportunities to leverage COPA in the delivery and remote management of controlled oral liquid medications for chronic pain and opioid addiction medication assisted therapy, as the Company believes they have the greatest need for the benefits of COPA’s features.
In the future, it will look to expand COPA usage into a broader set of drug therapeutics, possible clinical applications, and new businesses that manage the commercialization and data analytics provided by electronic devices to improve outcomes and reduce risk.

Company’s Keywords:

virtual care, healthcare it, healthcare technology, healthcare ai, medical device